Novo Nordisk (NVO) and Septerna (SEPN) said Wednesday they will collaborate on a project to develop and commercialize oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases.
Under the terms of the agreement, Septerna is eligible to receive about $2.2 billion from Novo Nordisk for upfront payments and research, development and commercial milestone payments, the companies said.
Septerna shares jumped 63% in premarket trading, while Novo Nordisk was 2.2% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.